alexa Construction Of A Recombinant Vaccinia Virus Expressing E Gene Of Japanese Encephalitis Virus And Immunogenicity In Pigs
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

16th Euro Global Summit and Expo on Vaccines & Vaccination
June 19-21, 2017 Paris, France

Hui-jun Lu
Changchun Veterinary Institute of CAAS, China
Posters & Accepted Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560-C1-058
Japanese encephalitis virus (JEV) can infect humans and swine with a high incidence rate in Asia. Consequently, the development of a vaccine that can provide rapid protection with minimal risk is an important research goal. A recombinant vaccinia virus (rVVTK/E3LΔ–E) containing envelope protease coding regions of JEV Yunnan0901 was constructed in this study. With the Tiantan strain of vaccinia virus (E3LΔ), an attenuated vaccine was constructed with TK gene deletion by homologous recombination. After screening and identification with a selectable marker, the recombinant vaccinia virus candidate vaccine was evaluated for its ability to induce humoral and cellular responses in pigs. The animals were vaccinated twice with a 21-day interval, and groups of animals were inoculated with the attenuated vaccine, vaccinia virus or phosphate buffered saline (PBS). All pigs vaccinated with rVVTK/E3LΔ–E developed specific anti-JEV antibodies and neutralizing antibodies. Splenocytes from pigs immunized with rVVTK/E3LΔ–E showed higher levels of T-lymphocyte proliferation, the greatest amounts of interferon-γ and interleukin (IL)-2, and moderate amounts of IL-4 and IL-10 in the presence of JEV. Vaccination with rVVTK/E3LΔ–E provided greater protection than that by the attenuated vaccine against JEV challenge. Moreover, pigs inoculated with the recombinant vaccine rVVTK/E3LΔ–E showed a lower virus load than those given the attenuated vaccine. Our findings indicated that rVVTK/E3LΔ–E might be an attractive candidate vaccine for preventing JEV infection.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version